DNLI · XBRL financial data

Denali Therapeutics financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DNLI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	336	49	108	331	0	0
Revenue from contracts with customers	336	49	105	331	0	0
Research and development	213	265	359	424	396	419
General and administrative	60	79	90	103	105	137
Total operating expenses	273	344	449	527	502	555
Operating income (loss)	63	(296)	(341)	(197)	(487)	(555)
Income tax expense (benefit)	(1)	(1)	0	0	0	0
Net income (loss)	71	(291)	(326)	(145)	(423)	(513)
Earnings per share, basic USD per share	0.65	(2.39)	(2.60)	(1.06)	(2.57)	(2.97)
Earnings per share, diluted USD per share	0.63	(2.39)	(2.60)	(1.06)	(2.57)	(2.97)
Weighted average shares, basic millions of shares	109	122	126	137	164	173
Weighted average shares, diluted millions of shares	113	122	126	137	164	173

Fiscal years (DNLI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	507	293	218	127	175	205
Marketable securities	963	572	1,118	907	657	663
Marketable securities, non-current	33	425	0	0	359	98
Accounts receivable	9	—	—	—	—	0
Inventory	—	—	—	—	—	0
Prepaid and other current assets	20	31	36	30	32	33
Total current assets	1,496	897	1,372	1,064	864	901
Property and equipment, net	41	39	44	46	55	52
Right-of-use asset	33	31	30	26	23	19
Total assets	1,604	1,404	1,460	1,154	1,374	1,145
Accounts payable	1	5	3	9	11	3
Accrued liabilities	8	—	67	68	91	95
Total current liabilities	72	378	364	78	102	98
Lease liability, non-current	64	59	53	45	37	27
Total liabilities	454	442	418	123	144	131
Accumulated deficit	(354)	(645)	(971)	(1,116)	(1,539)	(2,052)
Total stockholders' equity	1,151	962	1,042	1,031	1,230	1,014
Total liabilities and equity	1,604	1,404	1,460	1,154	1,374	1,145
Common shares outstanding (cover page) millions of shares	121	123	137	139	145	159

Fiscal years (DNLI's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	71	(291)	(326)	(145)	(423)	(513)
Stock-based compensation	50	85	100	108	103	100
Depreciation and amortization	9	9	10	17	8	11
Net cash from operating activities	416	(211)	(245)	(358)	(348)	(413)
Purchases of property and equipment	3	9	18	13	16	10
Net cash from investing activities	(623)	(22)	(141)	249	(89)	255
Proceeds from issuing common stock	194	0	296	0	0	—
Net cash from financing activities	635	19	311	18	484	189
Net change in cash	428	(214)	(75)	(91)	48	32

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Denali Therapeutics	103	18	(117)*	160.3M	4.4 quarters	Q3 FY26 10-QSep 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Schrodinger	247	64	(48)*	not reported	10.9 quarters	Q3 FY26 10-QSep 30, 2026
Mannkind	41	102	(35)*	321.6M	4.2 quarters	Q3 FY26 10-QSep 30, 2026
Novavax	222	68	(94)*	165.0M	9.4 quarters	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Innoviva	581	106	42*	71.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 9:44 PM ET. The filing on SEC.gov is the record.